Colorectal malignancy (CRC) remains among the leading factors behind cancer related fatalities in america. 20-223 strength. In CDK5 and CDK2 kinase assays, 20-223 was 3.5-fold and 65.3-fold stronger than known clinically used CDK inhibitor, AT7519, respectively. Cell-based research evaluating phosphorylation of downstream substrates uncovered 20-223 inhibits the kinase activity of CDK5 and CDK2 in multiple… Continue reading Colorectal malignancy (CRC) remains among the leading factors behind cancer related